Skip to main content
CIZZLE BIOTECHNOLOGY HOLDINGS PLC logo

CIZZLE BIOTECHNOLOGY HOLDINGS PLC — Investor Relations & Filings

Ticker · CIZ ISIN · GB00BNG2VN02 LEI · 213800G3OS3SA2J1Y358 IL Professional, scientific and technical activities
Open in API
Filings indexed 305 across all filing types
Latest filing 2021-09-15 Regulatory Filings
Country GB United Kingdom
Listing IL CIZ

About CIZZLE BIOTECHNOLOGY HOLDINGS PLC

https://cizzlebiotechnology.com/

Cizzle Biotechnology Holdings PLC is a cancer diagnostics developer focused on the early detection of lung cancer. The company is advancing a non-invasive, cost-effective blood test designed to identify lung cancer at its earliest stages, often before symptoms appear. The test utilizes a proprietary CIZ1B biomarker and an advanced immunoassay. Its primary goal is to improve patient outcomes by enabling swift, curative medical intervention. The technology aims to streamline the diagnostic pathway, reduce reliance on CT scans which can have high false-positive rates, and eliminate unnecessary invasive follow-up procedures. The company, a spin-out from the University of York, is conducting clinical trials to support global regulatory approval and adoption of its technology.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1935 characters) and contains the header 'RNS Number : 8991L'. It announces a 'Price Monitoring Extension' related to trading on the London Stock Exchange. This is a brief, specific regulatory announcement that does not fit into the detailed categories like 10-K, ER, or IR. Since it is a direct announcement disseminated via the RNS service, and it is not announcing the publication of a larger report (like an earnings release or annual report), it falls best under the general 'Regulatory Filings' category, which serves as the fallback for miscellaneous regulatory updates.
2021-09-15 English
Encouraging progress on collaboration with SGSC
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated September 9, 2021. It contains an update regarding a collaboration and clinical trial results (ARCADIA study of AZD1656). The structure, inclusion of contact details for brokers/advisors, and the concluding statement referencing 'RNS, the news service of the London Stock Exchange' strongly indicate this is a regulatory news service announcement. Since it is a general update that doesn't fit perfectly into specific categories like ER, IR, or DIV, and is clearly a formal regulatory dissemination, the most appropriate classification is the general regulatory filing category.
2021-09-09 English
Collaboration with FairJourney Biologics
Regulatory Filings Classification · 1% confidence The document starts with an 'RNS Number' and is dated July 22, 2021. It announces a 'Collaboration with FairJourney Biologics to Develop Proprietary Antibodies for Early Lung Cancer Detection Tests'. The text is a formal announcement detailing a strategic business development, not a full financial report (like 10-K or IR), an earnings release (ER), or a proxy statement. The presence of the RNS header and the nature of the announcement (a material corporate event update) strongly suggest this is a general regulatory announcement disseminated via the London Stock Exchange's RNS system. Since it is a specific corporate update that doesn't fit perfectly into categories like M&A (TAR) or Capital Change (CAP), the most appropriate general regulatory filing category is RNS, which serves as the fallback for miscellaneous regulatory announcements.
2021-07-22 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content discusses a 'Second Price Monitoring Extension' related to trading activity, which is a specific regulatory or market operational announcement. Since this type of announcement (trading halt/extension notice) does not fit into the specific categories like 10-K, ER, or DIV, and it is a direct regulatory/exchange notification, the most appropriate classification is the general regulatory announcement fallback category, RNS.
2021-07-09 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (2044 characters) and contains the header 'RNS Number : 8225E'. It discusses an extension to the 'Price Monitoring Extension' for a security and includes boilerplate text about RNS being the news service of the London Stock Exchange, approved by the FCA. This format is characteristic of a general regulatory announcement disseminated via the RNS system, rather than a specific financial report (like 10-K, IR, ER) or a specific corporate action (like DIV, DIRS). Since it is a general regulatory notification distributed through the RNS service, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such announcements.
2021-07-09 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document is very short (2028 chars) and its primary content is an announcement regarding a 'Second Price Monitoring Extension' for a security, explicitly stating it is an 'RNS Number' and is provided by 'RNS, the news service of the London Stock Exchange.' This structure—a brief notification about a market event or status update distributed via the RNS system—fits best under the general Regulatory Filings category, as there is no specific code for 'Price Monitoring Extension' and it is not a core financial report (like 10-K, IR, ER). It is a regulatory market notice.
2021-07-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.